 | |
| Clinical data | |
|---|---|
| Trade names | Upstène |
| Other names | LM-5008 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.058.569 |
| Chemical and physical data | |
| Formula | C15H20N2 |
| Molar mass | 228.339 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Indalpine, sold under the brand name Upstène, is a selective serotonin reuptake inhibitor (SSRI) that was briefly marketed as an antidepressant for treatment of depression.[1][2][3][4] It was marketed in France and a few other European countries.[4]
Indalpine is a selective serotonin reuptake inhibitor (SSRI) and antihistamine.[2]
Indalpine was discovered by 1977 and was introduced for medical use in France in 1983.[2][3] Two years later, in 1985, it was withdrawn from the market due to toxicity.[2][4] Indalpine has sometimes been said to be the first SSRI.[2][3] However, it was preceded by the SSRI zimelidine (Zelmid), which was discovered in 1969 and was introduced to the market in 1981 (then similarly withdrawn due to toxicity in 1983).[2][5][4]
- ^ Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 988–. ISBN 978-1-4757-2085-3.
- ^ a b c d e f Shorter E (2008). Before Prozac: The Troubled History of Mood Disorders in Psychiatry. Oxford University Press. pp. 15, 175, 221. ISBN 978-0-19-970933-5. Retrieved 12 August 2024.
- ^ a b c Healy D (14 October 2020). The Psychopharmacologists III (PDF). CRC Press. doi:10.4324/9781003058892-1. ISBN 978-1-003-05889-2.
It now seems clomipramine is useful for OCD because of its action on the 5HT system. This leads on to a Rhône-Poulenc drug which as I understand it was the first SSRI to be released clinically – Upstene, Indalpine. Can you tell me anything about it? Br: Well it wasn't made in Rhône-Poulenc. It was Fournier Freres, who were part of Pharmuka, who in turn became part of Rhône-Poulenc. Indalpine was launched in 1983. Gr: It was withdrawn because of side effects, neutropenia supposedly but that was not all. This drug had been launched before all the carcinogenicity results were in and when they were all available the drug had to be withdrawn. [...] Of 500,000 patients treated in 1984, the Pharmacovigilance committee had reports of 30 cases of neutropenia. Upstene in fact won the Prix Galien for pharmaceutical innovation in 1983.
- ^ a b c d "'Let Them Eat Prozac' - Introduction: The SSRI Issues" (PDF). Retrieved 12 August 2024.
- ^ Cite error: The named reference
Healy2004was invoked but never defined (see the help page).